Close Search
JDDonline - Journal of Drugs in Dermatology
  • Home
  • Issues
    • Current Issue
    • eJDD
    • Featured Articles
    • Archived Issues
    • Supplement Library
    • Case Reports
    • Unlocked Access
    • JDD Corner
    • Clinical Solutions
  • Topics
    • Atopic Dermatitis
    • Oats in Skincare
    • Oncoderm
    • Pigmentary Disorders
    • Psoriasis
    • Inclusive Dermatology Atlas
    • Social and Technology
    • Latest News
  • CME
    • CME Activities
  • Multimedia
    • JDD Corner
    • Video Abstracts
    • Podcast
    • Webinars
    • Translational Lecture Series
    • Video Pearls
  • Info
    • About JDD
    • Advertisers
      • Media Kit
      • Podcast Sponsorship
      • Reprints Contact Us
    • Authors
      • Instructions to Authors
      • Submit a Manuscript
      • Author and Peer Review Login
    • Editorial Board
    • Events
    • Contact Editorial
    • Why Publish in the JDD?
    • Institutional, Library, & Corporate Subscriptions
    • Reprints Contact Us
    • SanovaWorks
  • Inclusive Derm Atlas
    • Online Gallery
    • Digital Edition
  • Subscribe Now
  • Log In
  • x-twitter facebook linkedin instagram
Mar 31
Love0

INDIVIDUAL ARTICLE: Real World Use of Topical Tranexamic Acid Serum in Patients With Hyperpigmentation

By Chuck Lin No Comments
INTRODUCTIONHyperpigmentation and dyschromia are amongst the most common dermatologic concerns for patients seeking care.1 They can affect patients of all skin types and ages, and most commonly occurs after inflammation…
Read More
Mar 31
Love0

FULL SUPPLEMENT: Real World Cases of a Novel Topical Tranexamic Acid Serum in Treatment of Hyperpigmentation

By Chuck Lin No Comments
In this issue:INDIVIDUAL ARTICLE: Real World Use of Topical Tranexamic Acid Serum in Patients With HyperpigmentationHyperpigmentation and dyschromia are amongst the most common dermatologic concerns for patients seeking care.1 They…
Read More
Mar 31
Love0

Successful Treatment of Dystrophic Epidermolysis Bullosa With the JAK1 Inhibitor Abrocitinib

By Chuck Lin No Comments
INTRODUCTIONDystrophic epidermolysis bullosa (DEB), caused by mutations in COL7A1 is characterized by the development of blisters, bullae, and erosions following minor trauma to the skin and mucous membranes, with healing…
Read More
Mar 30
Love0

Objective Measures Needed: Dermatology Program Directors’ Perspectives on the USMLE Step 1 Pass/Fail Transition

By Chuck Lin No Comments
INTRODUCTIONThe United States Medical Licensing Examination (USMLE) will stop reporting a 3-digit numerical score and begin reporting a pass/fail outcome at the end of January 2022.1,2 The proposal for this…
Read More
Mar 30
Love0

The Dermoepidermal Junction as the Initiation Point for Reversal of Dermatoporosis

By Chuck Lin No Comments
INTRODUCTIONDermatoporosis is a term first coined by Kaya and Saurat in 2007, describing progressive skin thinning, extracellular matrix (ECM) degradation, vascular fragility with resultant purpura, and general vulnerability of the…
Read More
Mar 30
Love0

The State of Primary Hyperhidrosis: Therapeutic Advancements and National Representation

By Chuck Lin No Comments
INTRODUCTIONHyperhidrosis (HH) is defined as excessive sweating beyond the physiologic requirements of thermoregulation.1 HH is classified as either primary (idiopathic) or secondary to an underlying medical condition or medication.1 Primary…
Read More
Mar 30
Love0

Diagnostic Accuracy and Pitfalls of Publicly Available Artificial Intelligence Models for Nail Disorders

By Chuck Lin No Comments
INTRODUCTIONNail disorders encompass a broad spectrum of infectious, inflammatory, neoplastic, and traumatic conditions that may present with overlapping clinical features. They represent approximately 10% of all dermatologic conditions, accounting for…
Read More
Mar 30
Love0

Patient Interest in Dermatologists in the United States: A 20-Year Google Trends and Workforce Analysis

By Chuck Lin No Comments
INTRODUCTIONIn recent years, there has been a notable increase in attention to and financial support for dermatology.1,2 Skin conditions now rank as the fourth leading contributor to nonfatal disease burden…
Read More
Mar 30
Love0

Isotretinoin Does Not Increase the Risk of Inflammatory Bowel Disease: A TriNetX Retrospective Cohort Analysis

By Chuck Lin No Comments
INTRODUCTIONAcne vulgaris is one of the most common chronic dermatologic conditions globally and often significantly affects quality of life. For moderate to severe and treatment-resistant acne, oral isotretinoin remains one…
Read More
Mar 30
Love0

Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature

By Chuck Lin No Comments
INTRODUCTIONPsoriasis is a chronic inflammatory skin condition, affecting approximately three percent of the United States population. While modern therapeutic options for psoriasis have greatly improved symptom management and disease outcomes,…
Read More
Mar 26
Love0

Remibrutinib: Insights Into Its Mechanism of Action and Use for Dermatologic Conditions

By Chuck Lin No Comments
INTRODUCTIONChronic spontaneous urticaria (CSU) is a chronic, debilitating condition characterized by recurrent wheals and/or angioedema.1 Symptoms occur daily or nearly daily for at least 6 weeks, with angioedema reported in…
Read More
Mar 25
Love0

Rapid Clearance of Lichen Planus With Topical Tapinarof

By Chuck Lin No Comments
INTRODUCTIONLichen Planus (LP) is an auto-inflammatory idiopathic condition with unclear etiology, believed to be an auto-reactive response of T-cell-mediated damage after exposure to an inciting antigen. LP presents as pruritic,…
Read More
« Previous
NextPrevious »

Search page

Advertisement

Popular

  • Hair Loss Awareness Month August 7, 2026
  • “Please sir, I want some more:” When Rescue Becomes Routine With Prednisone in IBD Care August 7, 2026
  • “Please sir, I want some more:” When Rescue Becomes Routine With Prednisone in IBD Care August 7, 2026
  • Photoprotection 2026: Clinical Updates, Global Trends, and the US Regulatory Evolution August 6, 2026
  • GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity August 6, 2026

Advertisement

News Topics

  • Inclusive Derm Atlas
  • Atopic Dermatitis
  • CME
  • Featured Articles
  • Issue Highlights
  • Oats in Skincare
  • Oncoderm
  • Pigmentary Disorders
  • Psoriasis
  • Skin of Color
CONTACT US     |      FEEDBACK    |      TERMS     |      COOKIE POLICY    |     PRIVACY    |      EDITORIAL POLICY    |     ADVERTISING POLICY  |    MANAGE PREFERENCES  |  YOUR PRIVACY CHOICES

News Topics

  • Inclusive Derm Atlas
  • Atopic Dermatitis
  • CME
  • Featured Articles
  • Issue Highlights
  • Oats in Skincare
  • Oncoderm
  • Pigmentary Disorders
  • Psoriasis
  • Skin of Color
DermAtlas        Derm In-Review         PDE        Next Steps in Derm         Skin of Color Update     ODAC Dermatology, Aesthetic & Surgical Conference LVD        PDE       

Journal of Drugs in Dermatology

  • About Us
  • Contact Us
  • Contact Sales
  • Editorial Board
  • eJDD
  • Institutional, Library, & Corporate Subscriptions
  • Log In
  • Open Access
  • Permissions Request
  • Podcast Sponsorship
  • Subscription Info
  • Store

© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.

  • twitter
  • facebook
  • linkedin
  • instagram
Close Menu
  • Home
  • Issues
    • Current Issue
    • eJDD
    • Featured Articles
    • Archived Issues
    • Supplement Library
    • Case Reports
    • Unlocked Access
    • JDD Corner
    • Clinical Solutions
  • Topics
    • Atopic Dermatitis
    • Oats in Skincare
    • Oncoderm
    • Pigmentary Disorders
    • Psoriasis
    • Inclusive Dermatology Atlas
    • Social and Technology
    • Latest News
  • CME
    • CME Activities
  • Multimedia
    • JDD Corner
    • Video Abstracts
    • Podcast
    • Webinars
    • Translational Lecture Series
    • Video Pearls
  • Info
    • About JDD
    • Advertisers
      • Media Kit
      • Podcast Sponsorship
      • Reprints Contact Us
    • Authors
      • Instructions to Authors
      • Submit a Manuscript
      • Author and Peer Review Login
    • Editorial Board
    • Events
    • Contact Editorial
    • Why Publish in the JDD?
    • Institutional, Library, & Corporate Subscriptions
    • Reprints Contact Us
    • SanovaWorks
  • Inclusive Derm Atlas
    • Online Gallery
    • Digital Edition
  • Subscribe Now
  • Log In

Search

  • x-twitter
  • facebook
  • linkedin
  • instagram